Study in Nature Communications finds drug DDL-920 fully reproduces physical stroke rehabilitation effects in mice by restoring gamma oscillations in parvalbumin neurons.
Key Takeaways
Stroke is the leading cause of adult disability; no approved drugs exist for stroke recovery, only physical rehab with modest effectiveness.
UCLA team identified that stroke disrupts parvalbumin neurons and gamma oscillations in brain regions remote from the stroke site; successful rehab restores them.
DDL-920, developed at UCLA, targets parvalbumin neurons to recreate gamma oscillations and produced significant movement recovery in mouse stroke models.
Two candidate drugs were tested; DDL-920 was the effective one. Human trials require further safety and efficacy studies first.
The research identifies both a brain circuit mechanism underlying rehab effects and a concrete drug target within that circuit.
Hacker News Comment Review
The “first” claim is contested: one commenter points to Clinuvel’s afamelanotide, which showed positive stroke recovery results, raising questions about scope or definition of the claim.
Peripheral interest in neurogenesis supplements like Lion’s Mane surfaced, with a reply noting psilocybin has minimal research backing and that prohibition stalled psychedelic neuroscience for 50+ years.
Notable Comments
@seabass-salmon: flags Clinuvel’s afamelanotide as a prior candidate with positive results, suggesting the “first” framing may be narrower than headlines imply.
